UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 598

Sortiert nach

IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study

The Lancet (British edition), 2021-04, Vol.397 (10284), p.1564-1575

2021

Link zum Volltext

Verfügbarkeit prüfen

Dupilumab: A review of its use in the treatment of atopic dermatitis

Journal of the American Academy of Dermatology, 2018-03, Vol.78 (3), p.S28-S36

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

Journal of the American Academy of Dermatology, 2017-08, Vol.77 (2), p.310-317.e1

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Journal of the American Academy of Dermatology, 2017-03, Vol.76 (3), p.405-417

2017

Link zum Volltext

Verfügbarkeit prüfen

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

The Lancet (British edition), 2017-07, Vol.390 (10091), p.276-288

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

The New England journal of medicine, 2016-07, Vol.375 (4), p.345-356

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

The Lancet (British edition), 2018-08, Vol.392 (10148), p.650-661

2018

Link zum Volltext

Verfügbarkeit prüfen

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Journal of the American Academy of Dermatology, 2016-05, Vol.74 (5), p.841-850

2016

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics

Journal of the American Academy of Dermatology, 2013-11, Vol.69 (5), p.729-735

2013

Link zum Volltext

Verfügbarkeit prüfen

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

The New England journal of medicine, 2016-08, Vol.375 (5), p.422-434

2016

Link zum Volltext

Verfügbarkeit prüfen

Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study

Journal of the American Academy of Dermatology, 2020-06, Vol.82 (6), p.1305-1313

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

The New England journal of medicine, 2018-10, Vol.379 (14), p.1313-1321

2018

Link zum Volltext

Verfügbarkeit prüfen

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

The New England journal of medicine, 2017-04, Vol.376 (16), p.1551-1560

2017

Link zum Volltext

Verfügbarkeit prüfen

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

Journal of the American Academy of Dermatology, 2023-01, Vol.88 (1), p.29-39

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinical meaningfulness of complete skin clearance in psoriasis

Journal of the American Academy of Dermatology, 2016-07, Vol.75 (1), p.77-82.e7

2016

Link zum Volltext

Verfügbarkeit prüfen

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial

Journal of the American Academy of Dermatology, 2018-08, Vol.79 (2), p.277-286.e10

2018

Link zum Volltext

Verfügbarkeit prüfen

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

Journal of allergy and clinical immunology, 2020-03, Vol.145 (3), p.877-884

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

The Lancet (British edition), 2008-05, Vol.371 (9625), p.1665-1674

2008

Link zum Volltext

Verfügbarkeit prüfen

The psychosocial impact of hidradenitis suppurativa

Journal of the American Academy of Dermatology, 2015-11, Vol.73 (5), p.S19-S22

2015

Link zum Volltext

Verfügbarkeit prüfen

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

The Lancet (British edition), 2021-06, Vol.397 (10290), p.2151-2168

2021

Link zum Volltext

Verfügbarkeit prüfen

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

The Lancet (British edition), 2021-02, Vol.397 (10273), p.487-498

2021

Link zum Volltext

Verfügbarkeit prüfen

Bimekizumab versus Adalimumab in Plaque Psoriasis

The New England journal of medicine, 2021-07, Vol.385 (2), p.130-141

2021

Link zum Volltext

Verfügbarkeit prüfen

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

Journal of the American Academy of Dermatology, 2023-01, Vol.88 (1), p.40-51

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2020-06, Vol.156 (6), p.649

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

The Lancet (British edition), 2008-05, Vol.371 (9625), p.1675-1684

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 598

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(576)
Mit Volltextzugriff
(530)

Publikationsform

Sprache

Englisch
(598)
Japanisch
(46)

Erscheinungsjahr

n.n

Thema

Science & Technology
(370)
Life Sciences & Biomedicine
(353)
Humans
(300)
Dermatology
(255)
Female
(186)
Male
(174)
Adult
(163)
Psoriasis
(162)
Psoriasis - Drug Therapy
(161)
Treatment Outcome
(150)
Middle Aged
(148)
Double-Blind Method
(119)
Severity Of Illness Index
(107)
Biological And Medical Sciences
(104)
Medical Sciences
(101)
Aged
(77)
Antibodies, Monoclonal - Therapeutic Use
(70)
Psoriasis. Parapsoriasis. Lichen
(70)
Clinical Trials
(57)
Drug Therapy
(56)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(15)

Menü

Weitere Dienste

Einstellungen

IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study

Dupilumab: A review of its use in the treatment of atopic dermatitis

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

Clinical meaningfulness of complete skin clearance in psoriasis

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

The psychosocial impact of hidradenitis suppurativa

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

Bimekizumab versus Adalimumab in Plaque Psoriasis

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Suchergebnisse filtern